View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 29, 2021

Meissa’s intranasal Covid-19 shot induces robust antibody response in trial

In preclinical studies, the vaccine induced mucosal and systemic antibodies against wild-type SARS-CoV-2 challenge.

Meissa Vaccines has reported that its intranasal Covid-19 vaccine, MV-014-212, generated a robust nasal Immunoglobulin A (IgA) antibody response in seropositive and seronegative adults in Phase I clinical trial.

The live attenuated vaccine is built on the recombinant respiratory syncytial virus (RSV) AttenuBlock platform of Meissa.

It has been designed to be well-attenuated, genetically stable and optimised to offer strong and long-lasting immunity.

The latest initial results are from an interim analysis conducted on 49 subjects.

Of the doses ranging from 10^3-10^5 PFU analysed in the trial, the 10^5 PFU dose stimulated nasal IgA antibody levels that were in line with natural immunity to Covid-19 infection.

The safety data at all the tested dose levels of the vaccine showed MV-014-212 is greatly attenuated, without any infectious vaccine virus seen in trial subjects.

Furthermore, no serious adverse events linked to the vaccine were observed so far.

Currently, the Phase I trial is underway enrolling subjects with full data anticipated next year.

Meissa Vaccines chief medical officer Robert Walker said: “The preliminary clinical data indicate a single, adjuvant-free, needle-free dose of Meissa’s Covid-19 intranasal vaccine can stimulate a nasal IgA antibody response similar to that seen after SARS-CoV-2 infection, with an important difference – safety.

“We will continue to advance Meissa’s Covid-19 intranasal vaccine in this Phase I clinical trial in adults, and we plan to evaluate it as a booster to complement injectable vaccines and initiate a Phase I paediatric study next year.”

The vaccine induced both mucosal and systemic antibodies and demonstrated greater protection against wild-type SARS-CoV-2 challenge in nonhuman primates in preclinical studies.

In addition, serum antibodies were found to neutralise wild-type SARS-CoV-2, as well as the Beta and Alpha variants of the virus.

Related Companies

Free Report
img

Reshape regional strategies to navigate global uncertainties

The COVID-19 crisis triggered one of the worst peacetime recessions globally. Even as several economies tread the path to recovery, the surge in COVID-19 cases and emergence of new variants, coupled with geopolitical tensions, will continue to cloud the global outlook.  The Global Risk report uses GlobalData’s proprietary Country Risk Index to determine the existing and future level of global risk by assessing over 50 key indicators, including:  
  • Macroeconomic 
  • Political 
  • Social
  • Technological 
  • Environmental 
  • Legal 
Use our Country Risk Index scores to help you understand future global risk and determine your business strategies, growth plans and investment portfolios. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU